Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

An Oxford study of cancer in children and young adults in England has found that fewer patients were diagnosed during the COVID-19 pandemic, but cancer diagnosis following admission to intensive care was higher.

Parent and child talking to doctor

A study of cancer in children and young adults in England has found that fewer patients were diagnosed during the COVID-19 pandemic.

The research, presented at the NCRI Festival by Dr Defne Saatci from the Nuffield Department of Primary Care Health Sciences, also shows that children who were diagnosed with cancer during the first wave of the pandemic were more likely to have been admitted to intensive care prior to their diagnosis.

These findings suggest COVID-19 has had a detrimental effect on early diagnosis of cancer in children and young people.


Spotting cancer early and starting treatment promptly gives children and young people the best chance of surviving. We already know that the COVID-19 pandemic led to worrying delays in diagnosis and treatment for many adults with cancer, so we wanted to understand how the pandemic affected children’s cancer services.
- Dr Defne Saatci

 Dr Saatci and her colleagues used a general practice database called QResearch to study the numbers of different cancers diagnosed in children and young adults up to the age of 25 in the first wave of the pandemic, between 1 February and 15 August 2020. They compared this with diagnoses during the same time period in the three preceding pre-pandemic years. They also looked at the amount of time between diagnosis and the start of treatment and whether patients were diagnosed after being admitted to intensive care.

During the first wave, the researchers found that 380 patients were diagnosed with a brain tumour, lymphoma, leukaemia, sarcoma or renal tumour. This is approximately 17% lower than in previous years.

 They found that the average time between diagnosis and the start of treatment was slightly shorter during the first COVID-19 wave but that children were more than twice as likely to be admitted to intensive care before their cancer was diagnosed.


We found that more children were admitted to intensive care prior to their cancer diagnosis during the pandemic. A possible explanation is that these children waited longer to see a doctor and therefore may have been more unwell at the time of their diagnosis. Together with the lower numbers of cancer diagnoses in the first wave, this study suggests COVID-19 has had a serious impact on early diagnosis in this group of patients.

As we recover from the pandemic, it’s vital that we get diagnosis of cancer in children and young people back on track as quickly as possible.
- Lead researcher, Professor Julia Hippisley-Cox

Dr Saatci and her colleagues will now go on to study the impact of the subsequent waves of COVID-19 on diagnosis of childhood cancer in England.

Similar Stories

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

Automated assessment of pathology image quality

The new Oxford-developed artificial intelligence tool PathProfiler automates the quality control of large retrospective pathology image datasets to increase their usability in downstream research.